Biogen Inc. $BIIB Stake Raised by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 15.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,948 shares of the biotechnology company’s stock after purchasing an additional 5,041 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Biogen were worth $7,199,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Convergence Investment Partners LLC acquired a new stake in shares of Biogen during the 3rd quarter valued at $1,342,000. Caprock Group LLC acquired a new stake in shares of Biogen during the third quarter worth $742,000. Pitcairn Co. purchased a new stake in shares of Biogen during the second quarter valued at $936,000. Fluent Financial LLC acquired a new position in shares of Biogen in the 3rd quarter valued at $3,578,000. Finally, Leuthold Group LLC purchased a new position in Biogen in the 3rd quarter worth about $3,294,000. 87.93% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on BIIB shares. TD Cowen raised their target price on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 9th. The Goldman Sachs Group restated a “buy” rating on shares of Biogen in a research report on Monday, February 9th. Stifel Nicolaus raised their price objective on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Canaccord Genuity Group boosted their target price on shares of Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, HC Wainwright increased their target price on Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a report on Monday, February 9th. Twelve research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Biogen presently has a consensus rating of “Hold” and a consensus price target of $205.31.

Biogen Trading Down 3.8%

Biogen stock opened at $183.84 on Friday. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The stock has a market cap of $26.98 billion, a P/E ratio of 20.87, a P/E/G ratio of 1.46 and a beta of 0.15. The company’s fifty day simple moving average is $185.36 and its 200-day simple moving average is $170.24.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period last year, the company earned $3.44 earnings per share. Biogen’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts forecast that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.18% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.